Remove Healthcare Remove Pharma Remove Pharmaceutical manufacturing Remove Transportation
article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Let’s find out!

Pharma 52
article thumbnail

How can the pharma industry navigate issues in the global supply chain to minimise drug shortages?

pharmaphorum

Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.

Pharma 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

When people think about pharma, they often think about “big” pharma: large, faceless corporations. The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We But rare diseases are a particularly important and challenging focus area. Chiesi’s philosophy in action.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it. Clarify launched its real-world evidence on health disparities in 2021.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

Getting funding is going to be more difficult,” says Kyle Faget, partner and co-chair of Foley & Lardner’s Healthcare and Life Sciences Practices, Boston, Massachusetts. Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests.